Nahdi Medical Company (4164.SR)
SAR 120.8
(0.0%)
SAR 120.8
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 265.09 Million SAR | 188.8% |
| 2022 | 91.79 Million SAR | -90.42% |
| 2021 | 958.01 Million SAR | 322.87% |
| 2020 | 226.54 Million SAR | -73.2% |
| 2019 | 845.28 Million SAR | 597.01% |
| 2018 | -170.07 Million SAR | -40.28% |
| 2017 | -121.23 Million SAR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 548.77 Million SAR | 27.99% |
| 2024 Q1 | 428.75 Million SAR | 61.74% |
| 2023 Q2 | 211.81 Million SAR | 164.46% |
| 2023 Q1 | -328.61 Million SAR | -457.99% |
| 2023 FY | 265.09 Million SAR | 188.8% |
| 2023 Q4 | 265.09 Million SAR | 46.17% |
| 2023 Q3 | 181.35 Million SAR | -14.38% |
| 2022 Q4 | 91.79 Million SAR | -83.75% |
| 2022 Q3 | 565.01 Million SAR | 69.21% |
| 2022 Q2 | 333.91 Million SAR | -34.02% |
| 2022 Q1 | 506.11 Million SAR | -47.17% |
| 2022 FY | 91.79 Million SAR | -90.42% |
| 2021 FY | 958.01 Million SAR | 322.87% |
| 2021 Q3 | 834.9 Million SAR | -17.94% |
| 2021 Q2 | 1.01 Billion SAR | 0.88% |
| 2021 Q1 | 1 Billion SAR | 661.61% |
| 2021 Q4 | 958.01 Million SAR | 14.74% |
| 2020 Q1 | 575.18 Million SAR | 0.0% |
| 2020 FY | 226.54 Million SAR | -73.2% |
| 2020 Q4 | -179.57 Million SAR | 0.0% |
| 2019 FY | 845.28 Million SAR | 597.01% |
| 2018 FY | -170.07 Million SAR | -40.28% |
| 2017 FY | -121.23 Million SAR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 44.67 Million SAR | -493.417% |
| Al-Dawaa Medical Services Company | 2.23 Billion SAR | 88.165% |
| Al-Razi Medical Co. | 11.02 Million SAR | -2305.118% |
| Almujtama Alraida Medical Co. | 155.88 Million SAR | -70.056% |